Other combinations under investigations include AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1), with safety data reported from a phase I/I trial including patients with refractory solid organ malignancies (expansion in patients with cervical cancer) [29]. The gene discussed is CTLA4; the disease is cervical cancer.